Related Articles
Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan
Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer
Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy Corrigendum in /10.3892/mco.2021.2317
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Expression of total and phospho 4EBP1 in metastatic and non‑metastatic renal cell carcinoma